Celgene Makes Aggressive Push Into Solid Tumors With $2.9 Billion Abraxis Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
The pricey acquisition lands Celgene rights to the chemotherapeutic Abraxane and a proprietary nanoparticle formulation technology.